Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families

Cancer Prevention Research

Volumn 4, Issue 7, 2011, Pages 1002-1010

  Thorne, Heather ^a   Willems, Amber J ^a   Niedermayr, Eveline ^a   Hoh, Ivan M Y ^a   Li, Jason ^a   Clouston, David ^b   Mitchell, Gillian ^a   Fox, Stephen ^a   Hopper, John L ^c   Bolton, Damien ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Focus Pathology   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; DISEASE CARRIER; DISEASE COURSE; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; STRATIFICATION;

ADULT; AGED; AGED, 80 AND OVER; BRCA2 PROTEIN; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUTATION; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79960094457     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0397     Document Type: Article

References (38)

1. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008;26:211-8.
2. Fleshner NE, Lawrentschuk N. Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology 2009;73:S21-7.
3. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
4. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-8. (Pubitemid 27323331)
5. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:2918-21. (Pubitemid 38619665)
6. Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 2008;14:2953-61.
7. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-7. (Pubitemid 351161242)
8. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010;16:2115-21.
9. Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 2010;6:e1000995.
10. Giri VN, Coups EJ, Ruth K, Goplerud J, Raysor S, Kim TY, et al. Prostate cancer early detection program recruitment methods and show rates in men at high risk. J Urol 2009;182:2212-7.
11. McKinley JM, Weideman PC, Jenkins MA, Friedlander ML, Hopper JL, McLachlan SA, et al. Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. Hered Cancer Clin Pract 2007;5:161-3. (Pubitemid 47573518)
12. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008;99:371-4.
13. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010;103:918-24.
14. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006;8:R12.
15. Sobin LH, Gosporadowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. New Jersey: Wiley-Blackwell. 2009
16. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74. (Pubitemid 28445094)
17. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
18. Wu L, Patten N, Yamashiro CT, Chui B. Extraction and amplification of DNA from formalin-fixed, paraffin-embedded tissues. Appl Immuno-histochem Mol Morphol 2002;10:269-74. (Pubitemid 34988538)
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:187-220.
21. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
22. Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003;40:787-92. (Pubitemid 37311080)
23. Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in prostate carcinoma-outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005;103:943-51. (Pubitemid 40270070)
24. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929-35. (Pubitemid 47073499)
25. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
27. RACGP Guidelines for preventive activities in general practice.7th ed. Victoria, Australia: The Royal Australian College of General Practitioners. 2009.
28. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2011;107:28-39.
29. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
30. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
31. Telli ML, Ford JM. PARP Inhibitors in Breast Cancer. Clin Adv Hematol Oncol 2010;8:629-35.
32. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
33. Moro L, Arbini AA, Marra E, Greco M. Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma. Cell Oncol 2008;30:307-22. (Pubitemid 352032907)
34. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci 2008;99:553-63. (Pubitemid 351228573)
35. Woloshin S, Schwartz LM, Welch HG. Risk charts: putting cancer in context. J Natl Cancer Inst 2002;94:799-804. (Pubitemid 34705051)
36. Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, et al. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. Br J Cancer 2010;103:1103-8.
37. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009;41:1116-21.
38. Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet 2009;10:R77-R82.